Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

In the latest market close, Astrazeneca (AZN) reached $64.90, with a -1.35% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 1.57%. Elsewhere, the ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team.

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

Trump said overnight that the US would soon introduce a 'major tariff' on pharmaceuticals to force firms to relocate medicine production to America.